Table 1. Clinical characteristics and laboratory parameters of the patients.
| %/Mean (SD) | Number estimated (%) | |
|---|---|---|
| Age (years) | 64 (12) | 1189 (100) |
| Men | 60 | 1189 (100) |
| Duration of diabetes mellitus (years) | 10 (10) | 869 (73) |
| Current plus past cigarette smoking | 58 | 726 (61) |
| Therapeutic method | 1189 (100) | |
| Diet only/OHA/Insulin | 10/58/33 | |
| Body mass index (kg/m2) | 24.4 (4.1) | 1172 (99) |
| Hypertension | 77 | 1189 (100) |
| ACEi | 16 | 186 |
| ARB | 45 | 538 |
| Hyperlipidemia | 70 | 1189 (100) |
| HbA1c (%) | 7.0 (1.4) | 1119 (94) |
| Hemoglobin (g/dL) | 13.3 (1.6) | 1189 (100) |
| Men | 13.8 (1.6) | 709 |
| Women | 12.6 (1.4) | 480 |
| Diabetic nephropathy | 1189 (100) | |
| Stage I | 58 | 691 |
| Stage II | 19 | 226 |
| Stage III + IV | 23 | 272 |
| Estimated GFR (mL/min/1.73 m2) | 61.5 (19.4) | 1189 (100) |
| CKD stage | 1189 (100) | |
| 1 | 6 | 73 |
| 2 | 50 | 595 |
| 3 | 38 | 447 |
| 4 + 5 | 6 | 74 |
| Diabetic retinopathy | 43 | 801 (67) |
| Diabetic neuropathy | 81 | 845 (71) |
| Cerebrovascular disease | 15 | 1186 (100) |
| Coronary heart disease | 19 | 1187 (100) |
| Peripheral arterial disease | 4 | 1187 (100) |
ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; GFR, glomerular filtration rate; OHA, oral hypoglycemic agent.